Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$34.95 USD
+0.90 (2.64%)
Updated May 31, 2024 04:00 PM ET
After-Market: $34.95 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SYRE 34.95 +0.90(2.64%)
Will SYRE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SYRE
Spyre Therapeutics Announces Updated Share Structure
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
Spyre Therapeutics Expands Portfolio and Strengthens Leadership
Positive Outlook on Spyre Therapeutics’ IBD Pipeline and Financial Stability